1
|
Escobar A, Styrpejko DJ, Ali S, Cuajungco MP. Transmembrane 163 (TMEM163) protein interacts with specific mammalian SLC30 zinc efflux transporter family members. Biochem Biophys Rep 2022; 32:101362. [PMID: 36204728 PMCID: PMC9530847 DOI: 10.1016/j.bbrep.2022.101362] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2022] [Revised: 09/11/2022] [Accepted: 09/26/2022] [Indexed: 11/06/2022] Open
Abstract
Recently, we reported that TMEM163 is a zinc efflux transporter that likely belongs to the mammalian solute carrier 30 (Slc30/ZnT) subfamily of the cation diffusion facilitator (CDF) protein superfamily. We hypothesized that human TMEM163 forms functional heterodimers with certain ZNT proteins based on their overlapping subcellular localization with TMEM163 and previous reports that some ZNT monomers interact with each other. In this study, we heterologously expressed individual constructs with a unique peptide tag containing TMEM163, ZNT1, ZNT2, ZNT3, and ZNT4 (negative control) or co-expressed TMEM163 with each ZNT in cultured cells for co-immunoprecipitation (co-IP) experiments. We also co-expressed TMEM163 with two different peptide tags as a positive co-IP control. Western blot analyses revealed that TMEM163 dimerizes with itself but that it also heterodimerizes with ZNT1, ZNT2, ZNT3, and ZNT4 proteins. Confocal microscopy revealed that TMEM163 and ZNT proteins partially co-localize in cells, suggesting that they exist as homodimers and heterodimers in their respective subcellular sites. Functional zinc flux assays using Fluozin-3 and Newport Green dyes show that TMEM163/ZNT heterodimers exhibit similar efflux function as TMEM163 homodimers. Cell surface biotinylation revealed that the plasma membrane localization of TMEM163 is not markedly influenced by ZNT co-expression. Overall, our results show that the interaction between TMEM163 and distinct ZNT proteins is physiologically relevant and that their heterodimerization may serve to increase the functional diversity of zinc effluxers within specific tissues or cell types. TMEM163 protein heterodimerizes with ZNT1, ZNT2, ZNT3 and ZNT4 zinc efflux transporters. Partial co-localization of TMEM163 and ZNT proteins in cells suggests distinct roles as homodimers and heterodimers. Zinc efflux activity of TMEM163 or ZNT protein homodimers did not differ from their TMEM163/ZNT heterodimer counterparts. TMEM163/ZNT heterodimerization attests to the role of TMEM163 as a bona fide SLC30 protein family member.
Collapse
Affiliation(s)
| | | | - Saima Ali
- Department of Biological Science, USA
| | - Math P. Cuajungco
- Department of Biological Science, USA,Center for Applied Biotechnology Studies, California State University Fullerton, CA, 92831, USA,Corresponding author. Department of Biological Science, California State University Fullerton, 800 North State College Blvd, Fullerton, CA, 92831, USA.
| |
Collapse
|
2
|
Yan H, Yang S, Hou Y, Ali S, Escobar A, Gao K, Duan R, Kubisiak T, Wang J, Zhang Y, Xiao J, Jiang Y, Zhang T, Wu Y, Burmeister M, Wang Q, Cuajungco MP, Wang J. Functional Study of TMEM163 Gene Variants Associated with Hypomyelination Leukodystrophy. Cells 2022; 11:cells11081285. [PMID: 35455965 PMCID: PMC9031525 DOI: 10.3390/cells11081285] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2021] [Revised: 03/19/2022] [Accepted: 04/06/2022] [Indexed: 02/06/2023] Open
Abstract
Hypomyelinating leukodystrophies (HLDs) are a rare group of heterogeneously genetic disorders characterized by persistent deficit of myelin observed on magnetic resonance imaging (MRI). To identify a new disease-associated gene of HLD, trio-based whole exome sequencing was performed for unexplained patients with HLD. Functional studies were performed to confirm the phenotypic effect of candidate protein variants. Two de novo heterozygous variants, c.227T>G p.(L76R) or c.227T>C p.(L76P) in TMEM163 were identified in two unrelated HLD patients. TMEM163 protein is a zinc efflux transporter localized within the plasma membrane, lysosomes, early endosomes, and other vesicular compartments. It has not been associated with hypomyelination. Functional zinc flux assays in HeLa cells stably-expressing TMEM163 protein variants, L76R and L76P, revealed distinct attenuation or enhancement of zinc efflux, respectively. Experiments using a zebrafish model with knockdown of tmem163a and tmem163b (morphants) showed that loss of tmem163 causes dysplasia of the larvae, locomotor disability and myelin deficit. Expression of human wild type TMEM163 mRNAs in morphants rescues the phenotype, while the TMEM163 L76P and L76R mutants aggravated the condition. Moreover, poor proliferation, elevated apoptosis of oligodendrocytes, and reduced oligodendrocytes and neurons were also observed in zebrafish morphants. Our findings suggest an unappreciated role for TMEM163 protein in myelin development and add TMEM163 to a growing list of genes associated with hypomyelination leukodystrophy.
Collapse
Affiliation(s)
- Huifang Yan
- Department of Pediatrics, Peking University First Hospital, Beijing 100034, China; (H.Y.); (K.G.); (R.D.); (J.W.); (Y.Z.); (Y.J.); (Y.W.)
- Joint International Research Center of Translational and Clinical Research, Beijing 100191, China
- Beijing Key Laboratory of Molecular Diagnosis and Study on Pediatric Genetic Diseases, Beijing 100034, China
- Michigan Neuroscience Institute, University of Michigan, Ann Arbor, MI 48109, USA; (T.K.); (M.B.)
| | - Shuyan Yang
- Beijing Municipal Key Laboratory of Child Development and Nutriomics, Capital Institute of Pediatrics, Beijing 100020, China; (S.Y.); (T.Z.)
| | - Yiming Hou
- State Key Laboratory of Membrane Biology, Institute of Zoology, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Beijing 100101, China; (Y.H.); (Q.W.)
| | - Saima Ali
- Department of Biological Science, California State University, Fullerton, CA 92831, USA; (S.A.); (A.E.)
| | - Adrian Escobar
- Department of Biological Science, California State University, Fullerton, CA 92831, USA; (S.A.); (A.E.)
| | - Kai Gao
- Department of Pediatrics, Peking University First Hospital, Beijing 100034, China; (H.Y.); (K.G.); (R.D.); (J.W.); (Y.Z.); (Y.J.); (Y.W.)
| | - Ruoyu Duan
- Department of Pediatrics, Peking University First Hospital, Beijing 100034, China; (H.Y.); (K.G.); (R.D.); (J.W.); (Y.Z.); (Y.J.); (Y.W.)
| | - Thomas Kubisiak
- Michigan Neuroscience Institute, University of Michigan, Ann Arbor, MI 48109, USA; (T.K.); (M.B.)
| | - Junyu Wang
- Department of Pediatrics, Peking University First Hospital, Beijing 100034, China; (H.Y.); (K.G.); (R.D.); (J.W.); (Y.Z.); (Y.J.); (Y.W.)
| | - Yu Zhang
- Department of Pediatrics, Peking University First Hospital, Beijing 100034, China; (H.Y.); (K.G.); (R.D.); (J.W.); (Y.Z.); (Y.J.); (Y.W.)
| | - Jiangxi Xiao
- Department of Radiology, Peking University First Hospital, Beijing 100034, China;
| | - Yuwu Jiang
- Department of Pediatrics, Peking University First Hospital, Beijing 100034, China; (H.Y.); (K.G.); (R.D.); (J.W.); (Y.Z.); (Y.J.); (Y.W.)
- Beijing Key Laboratory of Molecular Diagnosis and Study on Pediatric Genetic Diseases, Beijing 100034, China
- Key Laboratory for Neuroscience, Ministry of Education/National Health and Family Planning Commission, Peking University, Beijing 100191, China
| | - Ting Zhang
- Beijing Municipal Key Laboratory of Child Development and Nutriomics, Capital Institute of Pediatrics, Beijing 100020, China; (S.Y.); (T.Z.)
| | - Ye Wu
- Department of Pediatrics, Peking University First Hospital, Beijing 100034, China; (H.Y.); (K.G.); (R.D.); (J.W.); (Y.Z.); (Y.J.); (Y.W.)
- Beijing Key Laboratory of Molecular Diagnosis and Study on Pediatric Genetic Diseases, Beijing 100034, China
| | - Margit Burmeister
- Michigan Neuroscience Institute, University of Michigan, Ann Arbor, MI 48109, USA; (T.K.); (M.B.)
- Departments of Computational Medicine & Bioinformatics, Psychiatry and Human Genetics, University of Michigan, Ann Arbor, MI 48109, USA
| | - Qiang Wang
- State Key Laboratory of Membrane Biology, Institute of Zoology, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Beijing 100101, China; (Y.H.); (Q.W.)
- Institute for Stem Cell and Regeneration, Chinese Academy of Sciences, Beijing 100101, China
| | - Math P. Cuajungco
- Department of Biological Science, California State University, Fullerton, CA 92831, USA; (S.A.); (A.E.)
- Center for Applied Biotechnology Studies, California State University, Fullerton, CA 92831, USA
- Correspondence: (M.P.C.); (J.W.)
| | - Jingmin Wang
- Department of Pediatrics, Peking University First Hospital, Beijing 100034, China; (H.Y.); (K.G.); (R.D.); (J.W.); (Y.Z.); (Y.J.); (Y.W.)
- Joint International Research Center of Translational and Clinical Research, Beijing 100191, China
- Beijing Key Laboratory of Molecular Diagnosis and Study on Pediatric Genetic Diseases, Beijing 100034, China
- Key Laboratory for Neuroscience, Ministry of Education/National Health and Family Planning Commission, Peking University, Beijing 100191, China
- Correspondence: (M.P.C.); (J.W.)
| |
Collapse
|
3
|
Cuajungco MP, Ramirez MS, Tolmasky ME. Zinc: Multidimensional Effects on Living Organisms. Biomedicines 2021; 9:biomedicines9020208. [PMID: 33671781 PMCID: PMC7926802 DOI: 10.3390/biomedicines9020208] [Citation(s) in RCA: 27] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2021] [Revised: 02/03/2021] [Accepted: 02/09/2021] [Indexed: 12/28/2022] Open
Abstract
Zinc is a redox-inert trace element that is second only to iron in abundance in biological systems. In cells, zinc is typically buffered and bound to metalloproteins, but it may also exist in a labile or chelatable (free ion) form. Zinc plays a critical role in prokaryotes and eukaryotes, ranging from structural to catalytic to replication to demise. This review discusses the influential properties of zinc on various mechanisms of bacterial proliferation and synergistic action as an antimicrobial element. We also touch upon the significance of zinc among eukaryotic cells and how it may modulate their survival and death through its inhibitory or modulatory effect on certain receptors, enzymes, and signaling proteins. A brief discussion on zinc chelators is also presented, and chelating agents may be used with or against zinc to affect therapeutics against human diseases. Overall, the multidimensional effects of zinc in cells attest to the growing number of scientific research that reveal the consequential prominence of this remarkable transition metal in human health and disease.
Collapse
|
4
|
Styrpejko DJ, Cuajungco MP. Transmembrane 163 (TMEM163) Protein: A New Member of the Zinc Efflux Transporter Family. Biomedicines 2021; 9:biomedicines9020220. [PMID: 33670071 PMCID: PMC7926707 DOI: 10.3390/biomedicines9020220] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2020] [Revised: 02/17/2021] [Accepted: 02/17/2021] [Indexed: 12/27/2022] Open
Abstract
A growing body of evidence continues to demonstrate the vital roles that zinc and its transporters play on human health. The mammalian solute carrier 30 (SLC30) family, with ten current members, controls zinc efflux transport in cells. TMEM163, a recently reported zinc transporter, has similar characteristics in both predicted transmembrane domain structure and function to the cation diffusion facilitator (CDF) protein superfamily. This review discusses past and present data indicating that TMEM163 is a zinc binding protein that transports zinc in cells. We provide a brief background on TMEM163’s discovery, transport feature, protein interactome, and similarities, as well as differences, with known SLC30 (ZnT) protein family. We also examine recent reports that implicate TMEM163 directly or indirectly in various human diseases such as Parkinson’s disease, Mucolipidosis type IV and diabetes. Overall, the role of TMEM163 protein in zinc metabolism is beginning to be realized, and based on current evidence, we propose that it is likely a new CDF member belonging to mammalian SLC30 (ZnT) zinc efflux transporter proteins.
Collapse
Affiliation(s)
- Daniel J. Styrpejko
- Department of Biological Science, California State University Fullerton, Fullerton, CA 92831, USA;
| | - Math P. Cuajungco
- Department of Biological Science, California State University Fullerton, Fullerton, CA 92831, USA;
- Center for Applied Biotechnology Studies, California State University Fullerton, Fullerton, CA 92831, USA
- Correspondence:
| |
Collapse
|
5
|
Abstract
Zinc (Zn2+) plays a vital role in the functioning of the cell. Cells have influx and efflux zinc transporters to regulate the levels of Zn2+ in the cytoplasm and organellar compartments to maintain homeostasis. We present a protocol to measure changes in cellular zinc concentrations using either a low-affinity membrane permeable or a high-affinity membrane impermeable fluorescent dye. Overall, zinc-specific fluorescent indicators using the assay can reliably detect the Zn2+ flux into or out of cultured cells. For complete details on the use and execution of this protocol, please refer to Sanchez et al. (2019). Reliable measure of zinc flux into or out of cultured adherent cells Amenable for use with fluorescent dyes or genetically encoded zinc indicators Data and statistical analyses can be done using a standard spreadsheet Adaptable assay for other metal ions that bind specific fluorescent dyes
Collapse
Affiliation(s)
- Saima Ali
- Department of Biological Science, California State University Fullerton, Fullerton, CA 92831, USA
- Corresponding author
| | - Math P. Cuajungco
- Department of Biological Science, California State University Fullerton, Fullerton, CA 92831, USA
- Center for Applied Biotechnology Studies, California State University Fullerton, Fullerton, CA 92831, USA
- Corresponding author
| |
Collapse
|
6
|
Escobar A, Styrpejko D, Ali S, Cuajungco MP. TMEM163 (ZNT11) protein interacts with distinct ZNT efflux transporters. FASEB J 2020. [DOI: 10.1096/fasebj.2020.34.s1.08750] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
| | | | - Saima Ali
- California State University Fullerton
| | | |
Collapse
|
7
|
Abstract
Aim Zinc is a critical divalent cation in mammalian brain, but its concentration must be strictly-controlled. Within certain subsets of glutamatergic neurons, ZnT3 (encoded by the Slc30a3 gene) facilitates the transport and storage of zinc in synaptic vesicles. It has been previously reported that Slc30a3 mRNA levels are perturbed in numerous neurodegenerative disorders. Given the growing evidence of zinc dysregulation in another neurodegenerative disease known as Mucolipidosis IV (MLIV), we hypothesized that abnormal ZnT3 expression would be observed in the brain of MLIV mouse model. Elucidating the link between abnormal ZnT3 and zinc levels could reveal the neuropathological correlates between MLIV and other age-related brain disorders. Methods Total RNAs from cortical tissues of Mucolipin-1 knockout (Mcoln1−/− KO) and Mcoln1+/+ wild-type (WT) littermate control mice were analyzed for differential gene expression (DGE) using RNA sequencing (RNA-seq). Real-time quantitative PCR (qPCR) and Western blot techniques were used to validate the data. Results RNA-seq analysis showed a marked decrease in baseline levels of Slc30a3 mRNA in Mcoln1−/− mice. Real-time qPCR and Western blot analyses confirmed that Slc30a3 transcripts and its protein levels were significantly reduced. Our observations add MLIV to a growing list of neurodegenerative diseases that parallels abnormal ZnT3 expression with zinc dyshomeostasis. Electronic supplementary material The online version of this article (10.1186/s13041-019-0446-3) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Jonathan Chacon
- Department of Biological Science, California State University Fullerton, 800 N. State College Blvd., Fullerton, CA, 92831, USA
| | - Lauren Rosas
- Department of Biological Science, California State University Fullerton, 800 N. State College Blvd., Fullerton, CA, 92831, USA
| | - Math P Cuajungco
- Department of Biological Science, California State University Fullerton, 800 N. State College Blvd., Fullerton, CA, 92831, USA. .,Center for Applied Biotechnology Studies, California State University Fullerton, Fullerton, CA, 92831, USA.
| |
Collapse
|
8
|
Chacon J, Cuajungco MP. Comparative De Novo Transcriptome Assembly of Notophthalmus viridescens RNA-seq Data using Two Commercial Software Programs. CALIF J HEALTH PROMOT 2018. [DOI: 10.32398/cjhp.v16i1.2123] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Background and Purpose: The reduction of cost and ease of using core laboratories or commercial sequencing companies have allowed biomedical and health researchers alike to employ reference-based genomic or transcriptomic sequencing (RNA-seq) projects to expand their work. Non-reference based data analysis, in cases of inexperienced researchers, become more challenging despite the availability of many open source and commercial software programs. Methods: We performed de novo assembly of RNA-seq data obtained from a non-model organism (Eastern Newt skin) to compare data output of two commercially available software workflows. Results: Our results show that the software packages performed satisfactorily albeit with differences in how the annotated and novel transcripts were identified and listed. Conclusion: Overall, we conclude that the use of commercial software platforms has a clear advantage to that of open source programs because of convenience with data analysis workflows. One caveat is that users need to know the software’s basic algorithm and technical approach, in order to determine the precision and validity of the data output. Thus, it is imperative that researchers fully evaluate the software according to their needs to determine their suitability.
Collapse
|
9
|
McEligot AJ, Cuajungco MP, Behseta S, Chandler L, Chauhan H, Mitra S, Rusmevichientong P, Charles S. Big Data Science Training Program at a Minority Serving Institution. CALIF J HEALTH PROMOT 2018. [DOI: 10.32398/cjhp.v16i1.2118] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
10
|
Chacon J, Cuajungco MP. Comparative De Novo Transcriptome Assembly of Notophthalmus viridescens RNA-seq Data using Two Commercial Software Programs. Calif J Health Promot 2018; 16:46-53. [PMID: 30381788 DOI: 10.32398/cjhp_20181601] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Background and Purpose The reduction of cost and ease of using core laboratories or commercial sequencing companies have allowed biomedical and health researchers alike to employ reference-based genomic or transcriptomic sequencing (RNA-seq) projects to expand their work. Non-reference based data analysis, in cases of inexperienced researchers, become more challenging despite the availability of many open source and commercial software programs. Methods We performed de novo assembly of RNA-seq data obtained from a non-model organism (Eastern Newt skin) to compare data output of two commercially available software workflows. Results Our results show that the software packages performed satisfactorily albeit with differences in how the annotated and novel transcripts were identified and listed. Conclusion Overall, we conclude that the use of commercial software platforms has a clear advantage to that of open source programs because of convenience with data analysis workflows. One caveat is that users need to know the software's basic algorithm and technical approach, in order to determine the precision and validity of the data output. Thus, it is imperative that researchers fully evaluate the software according to their needs to determine their suitability.
Collapse
Affiliation(s)
- Jonathan Chacon
- Department of Biological Science, California State University Fullerton
| | - Math P Cuajungco
- Department of Biological Science, California State University Fullerton.,Center for Applied Biotechnology Studies, California State University Fullerton
| |
Collapse
|
11
|
Sanchez V, Ali S, Cuajungco MP. Functional Characterization of Single Nucleotide Polymorphisms in the
TMEM163
Gene. FASEB J 2018. [DOI: 10.1096/fasebj.2018.32.1_supplement.541.13] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- Vanessa Sanchez
- Biological ScienceCalifornia State University FullertonFullertonCA
| | - Saima Ali
- Biological ScienceCalifornia State University FullertonFullertonCA
| | - Math P. Cuajungco
- Biological ScienceCalifornia State University FullertonFullertonCA
- Center for Applied Biotechnology StudiesCalifornia State University FullertonFullertonCA
| |
Collapse
|
12
|
Rosas L, Cuajungco MP. PAX5‐Induced Expression of Endogenous Mucolipin‐2 (
MCOLN2
) Gene in Human Glial and Neuronal Cell Lines: A Potential Gene Complementation Therapy Approach for Mucolipidosis IV. FASEB J 2018. [DOI: 10.1096/fasebj.2018.32.1_supplement.807.9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- Lauren Rosas
- Biological ScienceCalifornia State University FullertonFullertonCA
| | - Math P. Cuajungco
- Biological ScienceCalifornia State University FullertonFullertonCA
- Center for Applied Biotechnology StudiesCalifornia State University FullertonFullertonCA
| |
Collapse
|
13
|
Chacon J, Rosas L, Cuajungco MP. Differential Gene Expression Analysis of Brain Tissue RNA From Mucolipidosis IV Knockout Mice. FASEB J 2018. [DOI: 10.1096/fasebj.2018.32.1_supplement.788.7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- Jonathan Chacon
- Biological ScienceCalifornia State University FullertonFullertonCA
| | - Lauren Rosas
- Biological ScienceCalifornia State University FullertonFullertonCA
| | - Math P. Cuajungco
- Biological ScienceCalifornia State University FullertonFullertonCA
- Center for Applied Biotechnology StudiesCalifornia State University FullertonFullertonCA
| |
Collapse
|
14
|
McEligot AJ, Cuajungco MP, Behseta S, Chandler L, Chauhan H, Mitra S, Rusmevichientong P, Charles S. Big Data Science Training Program at a Minority Serving Institution: Processes and Initial Outcomes. Calif J Health Promot 2018; 16:1-5. [PMID: 30853869 PMCID: PMC6407619] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/09/2023] Open
|
15
|
Cuajungco MP, Kiselyov K. The mucolipin-1 (TRPML1) ion channel, transmembrane-163 (TMEM163) protein, and lysosomal zinc handling. Front Biosci (Landmark Ed) 2017; 22:1330-1343. [PMID: 28199205 DOI: 10.2741/4546] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Lysosomes are emerging as important players in cellular zinc ion (Zn2+) homeostasis. The series of work on Zn2+ accumulation in the neuronal lysosomes and the mounting evidence on the role of lysosomal Zn2+ in cell death during mammary gland involution set a biological precedent for the central role of the lysosomes in cellular Zn2+ handling. Such a role appears to involve cytoprotection on the one hand, and cell death on the other. The recent series of work began to identify the molecular determinants of the lysosomal Zn2+ handling. In addition to zinc transporters (ZnT) of the solute-carrier family type 30A (SLC30A), the lysosomal ion channel TRPML1 and the poorly understood novel transporter TMEM163 have been shown to play a role in the Zn2+ uptake by the lysosomes. In this review, we summarize the current knowledge on molecular determinants of the lysosomal Zn2+ handling, uptake, and release pathways, as well as discuss their possible roles in health and disease.
Collapse
Affiliation(s)
- Math P Cuajungco
- Department of Biological Science, and Center for Applied Biotechnology Studies, California State University Fullerton, Fullerton, CA, 92831, USA
| | - Kirill Kiselyov
- Dept. of Biological Sciences, University of Pittsburgh, 519 Langley Hall, 4249 Fifth Avenue, Pittsburgh, PA 15260, USA,
| |
Collapse
|
16
|
|
17
|
Abstract
It has been nearly 15 years since the suggestion that synaptically released Zn2+ might contribute to excitotoxic brain injury after seizures, stroke, and brain trauma. In the original “zinc-translocation” model, it was proposed that synaptically released Zn2+ ions penetrated postsynaptic neurons, causing injury. According to the model, chelating zinc in the cleft was predicted to be neuroprotective. This proved to be true: zinc chelators have proved to be remarkably potent at reducing excitotoxic neuronal injury in many paradigms. Promising new zinc-based therapies for stroke, head trauma, and epileptic brain injury are under development. However, new evidence suggests that the original translocation model was incomplete. As many as three sources of toxic zinc ions may contribute to excitotoxicity: presynaptic vesicles, postsynaptic zincsequestering proteins, and (more speculatively) mitochondrial pools. The authors present a new model of zinc currents and zinc toxicity that offers expanded opportunities for zinc-selective therapeutic chelation interventions.
Collapse
|
18
|
McEligot AJ, Behseta S, Cuajungco MP, Van Horn JD, Eng M, Toga AW. Wrangling Big Data Through Diversity, Research Education and Partnerships. CALIF J HEALTH PROMOT 2015. [DOI: 10.32398/cjhp.v13i3.1829] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
19
|
Cuajungco MP, Silva J, Habibi A, Valadez JA. The mucolipin-2 (TRPML2) ion channel: a tissue-specific protein crucial to normal cell function. Pflugers Arch 2015; 468:177-92. [PMID: 26336837 DOI: 10.1007/s00424-015-1732-2] [Citation(s) in RCA: 37] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2015] [Revised: 08/25/2015] [Accepted: 08/27/2015] [Indexed: 12/26/2022]
Abstract
The discovery of the TRPML subfamily of ion channels has created an exciting niche in the fields of membrane trafficking, signal transduction, autophagy, and metal homeostasis. The TRPML protein subfamily consists of three members, TRPML1, TRPML2, and TRPML3, which are encoded by MCOLN1, MCOLN2, and MCOLN3 genes, respectively. They are non-selective cation channels with six predicted transmembrane domains and intracellular amino- and carboxyl-terminus regions. They localize to the plasma membrane, endosomes, and lysosomes of cells. TRPML1 is associated with the human lysosomal storage disease known as mucolipidosis type IV (MLIV), but TRPML2 and TRPML3 have not been linked with a human disease. Although TRPML1 is expressed in many tissues, TRPML3 is expressed in a varied but limited set of tissues, while TRPML2 has a more limited expression pattern where it is mostly detected in lymphoid and myeloid tissues. This review focuses on TRPML2 because it appears to play an important, yet unrecognized role in the immune system. While the evidence has been mostly indirect, we present and discuss relevant data that strengthen the connection of TRPML2 with cellular immunity. We also discuss the functional redundancy between the TRPML proteins, and how such features could be exploited as a potential therapeutic strategy for MLIV disease. We present evidence that TRPML2 expression may complement certain phenotypic alterations in MLIV cells and briefly examine the challenges of functional complementation. In conclusion, the function of TRPML2 still remains obscure, but emerging data show that it may serve a critical role in immune cell development and inflammatory responses.
Collapse
Affiliation(s)
- Math P Cuajungco
- Department of Biological Science, California State University Fullerton, 800 N. State College Blvd., Fullerton, CA, 92831, USA. .,Center for Applied Biotechnology Studies, California State University Fullerton, Fullerton, CA, 92831, USA.
| | - Joshua Silva
- Department of Biological Science, California State University Fullerton, 800 N. State College Blvd., Fullerton, CA, 92831, USA
| | - Ania Habibi
- Department of Biological Science, California State University Fullerton, 800 N. State College Blvd., Fullerton, CA, 92831, USA
| | - Jessica A Valadez
- Department of Biological Science, California State University Fullerton, 800 N. State College Blvd., Fullerton, CA, 92831, USA
| |
Collapse
|
20
|
Stott KV, Wood SM, Blair JA, Nguyen BT, Herrera A, Mora YGP, Cuajungco MP, Murray SR. (p)ppGpp modulates cell size and the initiation of DNA replication in Caulobacter crescentus in response to a block in lipid biosynthesis. Microbiology (Reading) 2015; 161:553-64. [PMID: 25573769 DOI: 10.1099/mic.0.000032] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
Stress conditions, such as a block in fatty acid synthesis, signal bacterial cells to exit the cell cycle. Caulobacter crescentus FabH is a cell-cycle-regulated β-ketoacyl-acyl carrier protein synthase that initiates lipid biosynthesis and is essential for growth in rich media. To explore how C. crescentus responds to a block in lipid biosynthesis, we created a FabH-depletion strain. We found that FabH depletion blocks lipid biosynthesis in rich media and causes a cell cycle arrest that requires the alarmone (p)ppGpp for adaptation. Notably, basal levels of (p)ppGpp coordinate both a reduction in cell volume and a block in the over-initiation of DNA replication in response to FabH depletion. The gene ctrA encodes a master transcription factor that directly regulates 95 cell-cycle-controlled genes while also functioning to inhibit the initiation of DNA replication. Here, we demonstrate that ctrA transcription is (p)ppGpp-dependent during fatty acid starvation. CtrA fails to accumulate when FabH is depleted in the absence of (p)ppGpp due to a substantial reduction in ctrA transcription. The (p)ppGpp-dependent maintenance of ctrA transcription during fatty acid starvation initiated from only one of the two ctrA promoters. In the absence of (p)ppGpp, the majority of FabH-depleted cells enter a viable but non-culturable state, with multiple chromosomes, and are unable to recover from the miscoordination of cell cycle events. Thus, basal levels of (p)ppGpp facilitate C. crescentus' re-entry into the cell cycle after termination of fatty acid starvation.
Collapse
Affiliation(s)
- Kristina V Stott
- Department of Biology, Center for Cancer and Developmental Biology, Interdisciplinary Research Institute for the Sciences, California State University Northridge, Northridge, CA 91330-8303, USA
| | - Shannon M Wood
- Department of Biology, Center for Cancer and Developmental Biology, Interdisciplinary Research Institute for the Sciences, California State University Northridge, Northridge, CA 91330-8303, USA
| | - Jimmy A Blair
- Department of Chemistry, Williams College, Williamstown, MA 01267, USA
| | - Bao T Nguyen
- Department of Biology, Center for Cancer and Developmental Biology, Interdisciplinary Research Institute for the Sciences, California State University Northridge, Northridge, CA 91330-8303, USA
| | - Anabel Herrera
- Department of Biology, Center for Cancer and Developmental Biology, Interdisciplinary Research Institute for the Sciences, California State University Northridge, Northridge, CA 91330-8303, USA
| | - Yannet G Perez Mora
- Department of Biology, Center for Cancer and Developmental Biology, Interdisciplinary Research Institute for the Sciences, California State University Northridge, Northridge, CA 91330-8303, USA
| | - Math P Cuajungco
- Department of Biological Sciences, California State University Fullerton, Fullerton, CA 92831, USA Mental Health Research Institute, Melbourne Brain Centre, Parkville, Victoria 3052, Australia
| | - Sean R Murray
- Department of Biology, Center for Cancer and Developmental Biology, Interdisciplinary Research Institute for the Sciences, California State University Northridge, Northridge, CA 91330-8303, USA
| |
Collapse
|
21
|
McEligot AJ, Behseta S, Cuajungco MP, Van Horn JD, Toga AW. Wrangling Big Data Through Diversity, Research Education and Partnerships. Calif J Health Promot 2015; 13:vi-ix. [PMID: 27257409 PMCID: PMC4886736] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/05/2023] Open
|
22
|
Valadez JA, Cuajungco MP. PAX5 is the transcriptional activator of mucolipin-2 (MCOLN2) gene. Gene 2014; 555:194-202. [PMID: 25445271 DOI: 10.1016/j.gene.2014.11.003] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2014] [Revised: 10/25/2014] [Accepted: 11/03/2014] [Indexed: 10/24/2022]
Abstract
Transient receptor potential mucolipin (TRPML) proteins belong to the TRP superfamily of non-selective cation channels. The TRPML1, -2, and -3 proteins are encoded by Mucolipin (MCOLN)-1, -2 and -3 genes, respectively. TRPML1 has been associated with mucolipidosis type IV (MLIV), while no disease phenotype has been linked with TRPML2 or -3 protein. The TRPML proteins share high sequence similarities, form hetero-tetramers, and serve in membrane trafficking, autophagy, and metal homeostasis. Previous studies suggest that TRPML2 serves a role in the immune system; however, the evidence is mostly indirect. We hypothesize that if TRPML2 is involved in immune function its expression would be likely regulated by an immune-associated transcription factor protein. Thus, we set out to identify the core promoter region and the transcription factor responsible for MCOLN2 gene expression. Using dual-luciferase assay and over-expression analyses, we reveal for the first time that B-cell lineage specific activator protein (BSAP), also known as paired box 5 (PAX5), controls MCOLN2 expression. Specifically, heterologous expression of PAX5 in HEK-293 cells significantly increased endogenous MCOLN2 transcript and TRPML2 protein levels, while RNA interference targeting endogenous PAX5 reduced its effect. Site-directed mutagenesis studies showed that the core promoter and PAX5 binding region to be between -79 and -60 base pairs upstream of the transcriptional start site. Thus, our findings add to a growing list of evidence for TRPML2's possible involvement in the immune system. The knowledge gained from this study could be used to further characterize the role of TRPML2 in B-cell development and function.
Collapse
Affiliation(s)
- Jessica A Valadez
- Department of Biological Science, and Center for Applied Biotechnology Studies, California State University Fullerton, CA 92831, USA
| | - Math P Cuajungco
- Department of Biological Science, and Center for Applied Biotechnology Studies, California State University Fullerton, CA 92831, USA; Mental Health Research Institute, Melbourne Brain Centre, Parkville, Victoria 3052, Australia.
| |
Collapse
|
23
|
Cuajungco MP, Basilio LC, Silva J, Hart T, Tringali J, Chen CC, Biel M, Grimm C. Cellular zinc levels are modulated by TRPML1-TMEM163 interaction. Traffic 2014; 15:1247-65. [PMID: 25130899 DOI: 10.1111/tra.12205] [Citation(s) in RCA: 48] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2014] [Revised: 08/02/2014] [Accepted: 08/04/2014] [Indexed: 02/05/2023]
Abstract
Mucolipidosis type IV (MLIV) is caused by loss of function mutations in the TRPML1 ion channel. We previously reported that tissue zinc levels in MLIV were abnormally elevated; however, the mechanism behind this pathologic accumulation remains unknown. Here, we identify transmembrane (TMEM)-163 protein, a putative zinc transporter, as a novel interacting partner for TRPML1. Evidence from yeast two-hybrid, tissue expression pattern, co-immunoprecipitation, mass spectrometry and confocal microscopy studies confirmed the physical association of TMEM163 with TRPML1. This interaction is disrupted when a part of TMEM163's N-terminus was deleted. Further studies to define the relevance of their interaction revealed that the plasma membrane (PM) levels of TMEM163 significantly decrease when TRPML1 is co-expressed in HEK-293 cells, while it mostly localizes within the PM when co-expressed with a mutant TRPML1 that distributes mostly in the PM. Meanwhile, co-expression of TMEM163 does not alter TRPML1 channel activity, but its expression levels in MLIV patient fibroblasts are reduced, which correlate with marked accumulation of zinc in lysosomes when these cells are acutely exposed to exogenous zinc (100 μM). When TMEM163 is knocked down or when TMEM163 and TRPML1 are co-knocked down in HEK-293 cells treated overnight with 100 nm zinc, the cells have significantly higher intracellular zinc levels than untreated control. Overall, these findings suggest that TMEM163 and TRPML1 proteins play a critical role in cellular zinc homeostasis, and thus possibly explain a novel mechanism for the pathological overload of zinc in MLIV disease.
Collapse
Affiliation(s)
- Math P Cuajungco
- Department of Biological Science and Center for Applied Biotechnology Studies, California State University, Fullerton, CA, 92831, USA; Mental Health Research Institute, Melbourne Brain Centre, Parkville, VIC, 3052, Australia
| | | | | | | | | | | | | | | |
Collapse
|
24
|
Cuajungco MP, Podevin W, Valluri VK, Bui Q, Nguyen VH, Taylor K. Abnormal accumulation of human transmembrane (TMEM)-176A and 176B proteins is associated with cancer pathology. Acta Histochem 2012; 114:705-12. [PMID: 22244448 DOI: 10.1016/j.acthis.2011.12.006] [Citation(s) in RCA: 45] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2011] [Revised: 12/08/2011] [Accepted: 12/11/2011] [Indexed: 12/31/2022]
Abstract
Transmembrane (TMEM)-176A and 176B proteins belong to the MS4A family of proteins whose function in the immune system remains unclear. TMEM176A transcripts were previously shown to be elevated in liver cancer or kidney tissue with proteinuria, while marked changes in TMEM176B transcripts have been found in tolerated tissue allografts and neoplastic fibroblasts. To study the functional relationship between human TMEM176A and 176B and their putative link to cancer, we used polymerase chain reaction and biochemical assays. Here, we show that TMEM176A and 176B are widely expressed in all human tissues examined. Co-immunoprecipitation of heterologously expressed TMEM176A and 176B revealed direct physical interaction. To determine the relevance of such interaction to cancer pathology, we analyzed biopsied tissue samples from a variety of normal and cancer tissues. Our data reveal that human TMEM176A and 176B protein levels are significantly elevated in lymphoma, but not in normal tissues. The protein levels of TMEM176A are also significantly increased in lung carcinoma. Finally, analysis of the protein expression ratio of TMEM176A over 176B showed significant differences between normal and cancer tissues of the breast, lymph, skin, and liver, which indicates that both TMEM proteins could be potential useful markers for certain human cancers.
Collapse
|
25
|
Schredl AT, Perez Mora YG, Herrera A, Cuajungco MP, Murray SR. The Caulobacter crescentus ctrA P1 promoter is essential for the coordination of cell cycle events that prevent the overinitiation of DNA replication. Microbiology (Reading) 2012; 158:2492-2503. [PMID: 22790399 DOI: 10.1099/mic.0.055285-0] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
The master regulator CtrA oscillates during the Caulobacter cell cycle due to temporally regulated proteolysis and transcription. It is proteolysed during the G1-S transition and reaccumulates in predivisional cells as a result of transcription from two sequentially activated promoters, P1 and P2. CtrA reinforces its own synthesis by directly mediating the activation of P2 concurrently with repression of P1. To explore the role of P1 in cell cycle control, we engineered a mutation into the native ctrA locus that prevents transcription from P1 but not P2. As expected, the ctrA P1 mutant exhibits striking growth, morphological and DNA replication defects. Unexpectedly, we found CtrA and its antagonist SciP, but not DnaA, GcrA or CcrM accumulation to be dramatically reduced in the ctrA P1 mutant. SciP levels closely paralleled CtrA accumulation, suggesting that CtrA acts as a rheostat to modulate SciP abundance. Furthermore, the reappearance of CtrA and CcrM in predivisional cells was delayed in the P1 mutant by 0.125 cell cycle unit in synchronized cultures. High levels of ccrM transcription despite low levels of CtrA and increased transcription of ctrA P2 in the ctrA P1 mutant are two examples of robustness in the cell cycle. Thus, Caulobacter can adjust regulatory pathways to partially compensate for reduced and delayed CtrA accumulation in the ctrA P1 mutant.
Collapse
Affiliation(s)
- Alexander T Schredl
- Department of Biology, Center for Cancer and Developmental Biology, California State University Northridge, Northridge, CA 91330-8303, USA
| | - Yannet G Perez Mora
- Department of Biology, Center for Cancer and Developmental Biology, California State University Northridge, Northridge, CA 91330-8303, USA
| | - Anabel Herrera
- Department of Biology, Center for Cancer and Developmental Biology, California State University Northridge, Northridge, CA 91330-8303, USA
| | - Math P Cuajungco
- Mental Health Research Institute, Melbourne Brain Centre, Parkville, Victoria 3052, Australia.,Department of Biological Science, California State University Fullerton, Fullerton, CA 92831, USA
| | - Sean R Murray
- Department of Biology, Center for Cancer and Developmental Biology, California State University Northridge, Northridge, CA 91330-8303, USA
| |
Collapse
|
26
|
Affiliation(s)
| | | | - Quang Bui
- BiologyCalifornia State University FullertonFullertonCA
| | - Van Nguyen
- BiologyCalifornia State University FullertonFullertonCA
| | - Math P Cuajungco
- BiologyCalifornia State University FullertonFullertonCA
- Center for Applied Biotechnology StudiesCalifornia State University FullertonFullertonCA
| |
Collapse
|
27
|
Eichelsdoerfer JL, Evans JA, Slaugenhaupt SA, Cuajungco MP. Zinc dyshomeostasis is linked with the loss of mucolipidosis IV-associated TRPML1 ion channel. J Biol Chem 2010; 285:34304-8. [PMID: 20864526 DOI: 10.1074/jbc.c110.165480] [Citation(s) in RCA: 82] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Chelatable zinc is important in brain function, and its homeostasis is maintained to prevent cytotoxic overload. However, certain pathologic events result in intracellular zinc accumulation in lysosomes and mitochondria. Abnormal lysosomes and mitochondria are common features of the human lysosomal storage disorder known as mucolipidosis IV (MLIV). MLIV is caused by the loss of TRPML1 ion channel function. MLIV cells develop large hyperacidic lysosomes, membranous vacuoles, mitochondrial fragmentation, and autophagic dysfunction. Here, we observed that RNA interference of mucolipin-1 gene (TRPML1) in HEK-293 cells mimics the MLIV cell phenotype consisting of large lysosomes and membranous vacuoles that accumulate chelatable zinc. To show that abnormal chelatable zinc levels are indeed correlated with MLIV pathology, we quantified its concentration in cultured MLIV patient fibroblast and control cells with a spectrofluorometer using N-(6-methoxy-8-quinolyl)-p-toluene sulfonamide fluorochrome. We found a significant increase of chelatable zinc levels in MLIV cells but not in control cells. Furthermore, we quantified various metal isotopes in whole brain tissue of TRPML1(-/-) null mice and wild-type littermates using inductively coupled plasma mass spectrometry and observed that the zinc-66 isotope is markedly elevated in the brain of TRPML1(-/-) mice when compared with controls. In conclusion, we show for the first time that the loss of TRPML1 function results in intracellular chelatable zinc dyshomeostasis. We propose that chelatable zinc accumulation in large lysosomes and membranous vacuoles may contribute to the pathogenesis of the disease and progressive cell degeneration in MLIV patients.
Collapse
Affiliation(s)
- Jonathan L Eichelsdoerfer
- Department of Biological Science and Center for Applied Biotechnology Studies, California State University, Fullerton, California 92831, USA
| | | | | | | |
Collapse
|
28
|
Grimm C, Jörs S, Saldanha SA, Obukhov AG, Pan B, Oshima K, Cuajungco MP, Chase P, Hodder P, Heller S. Small molecule activators of TRPML3. ACTA ACUST UNITED AC 2010; 17:135-48. [PMID: 20189104 DOI: 10.1016/j.chembiol.2009.12.016] [Citation(s) in RCA: 92] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2009] [Revised: 12/22/2009] [Accepted: 12/31/2009] [Indexed: 11/28/2022]
Abstract
We conducted a high-throughput screen for small molecule activators of the TRPML3 ion channel, which, when mutated, causes deafness and pigmentation defects. Cheminformatics analyses of the 53 identified and confirmed compounds revealed nine different chemical scaffolds and 20 singletons. We found that agonists strongly potentiated TRPML3 activation with low extracytosolic [Na(+)]. This synergism revealed the existence of distinct and cooperative activation mechanisms and a wide dynamic range of TRPML3 activity. Testing compounds on TRPML3-expressing sensory hair cells revealed the absence of activator-responsive channels. Epidermal melanocytes showed only weak or no responses to the compounds. These results suggest that TRPML3 in native cells might be absent from the plasma membrane or that the protein is a subunit of heteromeric channels that are nonresponsive to the activators identified in this screen.
Collapse
Affiliation(s)
- Christian Grimm
- Departments of Otolaryngology-Head and Neck Surgery, Stanford University School of Medicine, Stanford, CA 94305, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Eichelsdoerfer JL, Evans J, Sorasaenee K, Morrison C, Linder M, Slaugenhaupt S, Cuajungco MP. Trace metal dyshomeostasis is associated with loss of TRPML1 ion channel function. FASEB J 2010. [DOI: 10.1096/fasebj.24.1_supplement.708.3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
| | - Jeffrey Evans
- Biological ScienceCalifornia State University FullertonFullertonCA
| | - Karn Sorasaenee
- Chemistry and BiochemistryCalifornia State University FullertonFullertonCA
| | - Chevaun Morrison
- Chemistry and BiochemistryCalifornia State University FullertonFullertonCA
| | - Maria Linder
- Chemistry and BiochemistryCalifornia State University FullertonFullertonCA
| | | | | |
Collapse
|
30
|
Samie MA, Grimm C, Evans JA, Curcio-Morelli C, Heller S, Slaugenhaupt SA, Cuajungco MP. The tissue-specific expression of TRPML2 (MCOLN-2) gene is influenced by the presence of TRPML1. Pflugers Arch 2010; 459:79-91. [PMID: 19763610 DOI: 10.1007/s00424-009-0716-5] [Citation(s) in RCA: 63] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2009] [Revised: 08/12/2009] [Accepted: 08/14/2009] [Indexed: 11/29/2022]
Abstract
Mucolipidosis type IV is a lysosomal storage disorder caused by the loss or dysfunction of the mucolipin-1 (TRPML1) protein. It has been suggested that TRPML2 could genetically compensate (i.e., become upregulated) for the loss of TRPML1. We thus investigated this possibility by first studying the expression pattern of mouse TRPML2 and its basic channel properties using the varitint-waddler (Va) model. Here, we confirmed the presence of long variant TRPML2 (TRPML2lv) and short variant (TRPML2sv) isoforms. We showed for the first time that, heterologously expressed, TRPML2lv-Va is an active, inwardly rectifying channel. Secondly, we quantitatively measured TRPML2 and TRPML3 mRNA expressions in TRPML1-/- null and wild-type (Wt) mice. In wild-type mice, the TRPML2lv transcripts were very low while TRPML2sv and TRPML3 transcripts have predominant expressions in lymphoid and kidney organs. Significant reductions of TRPML2sv, but not TRPML2lv or TRPML3 transcripts, were observed in lymphoid and kidney organs of TRPML1-/- mice. RNA interference of endogenous human TRPML1 in HEK-293 cells produced a comparable decrease of human TRPML2 transcript levels that can be restored by overexpression of human TRPML1. Conversely, significant upregulation of TRPML2sv transcripts was observed when primary mouse lymphoid cells were treated with nicotinic acid adenine dinucleotide phosphate, or N-(2-[p-bromocinnamylamino]ethyl)-5-isoquinoline sulfonamide, both known activators of TRPML1. In conclusion, our results indicate that TRPML2 is unlikely to compensate for the loss of TRPML1 in lymphoid or kidney organs and that TRPML1 appears to play a novel role in the tissue-specific transcriptional regulation of TRPML2.
Collapse
Affiliation(s)
- Mohammad A Samie
- Department of Biological Science, and Center for Applied, Biotechnology Studies, California State University Fullerton, 800 N State College Blvd, Fullerton, CA 92831, USA
| | | | | | | | | | | | | |
Collapse
|
31
|
Cuajungco MP, Grimm C, Heller S. TRP channels as candidates for hearing and balance abnormalities in vertebrates. Biochim Biophys Acta Mol Basis Dis 2007; 1772:1022-7. [PMID: 17300924 PMCID: PMC1961624 DOI: 10.1016/j.bbadis.2007.01.002] [Citation(s) in RCA: 54] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2006] [Revised: 01/05/2007] [Accepted: 01/09/2007] [Indexed: 12/19/2022]
Abstract
In this review, we summarize the potential functional roles of transient receptor potential (TRP) channels in the vertebrate inner ear. The history of TRP channels in hearing and balance is characterized at great length by the hunt for the elusive transduction channel of sensory hair cells. Such pursuit has not resulted in unequivocal identification of the transduction channel, but nevertheless revealed a number of candidates, such as TRPV4, TRPN1, TRPA1, and TRPML3. Much of the circumstantial evidence indicates that these TRP channels potentially play significant roles in inner ear physiology. Based on mutations in the corresponding mouse genes, TRPV4 and TRPML3 are possible candidates for human hearing, and potentially also balance disorders. We further discuss the role of the invertebrate TRP channels Nanchung, Inactive, and TRPN1 and how the functional analysis of these channels provides a link to vertebrate hearing and balance. In summary, only a few TRP channels have been analyzed thus far for a prospective role in the inner ear, and this makes the search for additional TRPs associated with inner ear function quite a tantalizing endeavor.
Collapse
Affiliation(s)
| | | | - Stefan Heller
- *Corresponding Author Mailing Address: Stanford University School of Medicine, Department of Otolaryngology – Head & Neck Surgery, 801 Welch Road, Stanford CA 94305, Tel: 650-724-8086,
| |
Collapse
|
32
|
Martinez-Monedero R, Corrales CE, Cuajungco MP, Heller S, Edge AS. Reinnervation of hair cells by auditory neurons after selective removal of spiral ganglion neurons. ACTA ACUST UNITED AC 2006; 66:319-31. [PMID: 16408287 PMCID: PMC1978539 DOI: 10.1002/neu.20232] [Citation(s) in RCA: 52] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
Abstract
Hearing loss can be caused by primary degeneration of spiral ganglion neurons or by secondary degeneration of these neurons after hair cell loss. The replacement of auditory neurons would be an important step in any attempt to restore auditory function in patients with damaged inner ear neurons or hair cells. Application of beta-bungarotoxin, a toxin derived from snake venom, to an explant of the cochlea eradicates spiral ganglion neurons while sparing the other cochlear cell types. The toxin was found to bind to the neurons and to cause apoptotic cell death without affecting hair cells or other inner ear cell types as indicated by TUNEL staining, and, thus, the toxin provides a highly specific means of deafferentation of hair cells. We therefore used the denervated organ of Corti for the study of neuronal regeneration and synaptogenesis with hair cells and found that spiral ganglion neurons obtained from the cochlea of an untreated newborn mouse reinnervated hair cells in the toxin-treated organ of Corti and expressed synaptic vesicle markers at points of contact with hair cells. These findings suggest that it may be possible to replace degenerated neurons by grafting new cells into the organ of Corti.
Collapse
Affiliation(s)
- Rodrigo Martinez-Monedero
- Department of Otology and Laryngology, Harvard Medical School, Boston, Massachusetts 02115
- Tillotson Unit for Cell Biology of the Inner Ear, Eaton-Peabody Laboratory, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts 02114
| | - C. Eduardo Corrales
- Department of Otology and Laryngology, Harvard Medical School, Boston, Massachusetts 02115
- Tillotson Unit for Cell Biology of the Inner Ear, Eaton-Peabody Laboratory, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts 02114
| | - Math P. Cuajungco
- Department of Otology and Laryngology, Harvard Medical School, Boston, Massachusetts 02115
- Tillotson Unit for Cell Biology of the Inner Ear, Eaton-Peabody Laboratory, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts 02114
| | - Stefan Heller
- Department of Otology and Laryngology, Harvard Medical School, Boston, Massachusetts 02115
- Tillotson Unit for Cell Biology of the Inner Ear, Eaton-Peabody Laboratory, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts 02114
- Program in Speech and Hearing Bioscience and Technology, Division of Health Science and Technology, Harvard & MIT, Cambridge, Massachusetts 02139
| | - Albert S.B. Edge
- Department of Otology and Laryngology, Harvard Medical School, Boston, Massachusetts 02115
- Tillotson Unit for Cell Biology of the Inner Ear, Eaton-Peabody Laboratory, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts 02114
- Program in Speech and Hearing Bioscience and Technology, Division of Health Science and Technology, Harvard & MIT, Cambridge, Massachusetts 02139
- Correspondence to: A. Edge ()
| |
Collapse
|
33
|
Cuajungco MP, Grimm C, Oshima K, D'hoedt D, Nilius B, Mensenkamp AR, Bindels RJM, Plomann M, Heller S. PACSINs bind to the TRPV4 cation channel. PACSIN 3 modulates the subcellular localization of TRPV4. J Biol Chem 2006; 281:18753-62. [PMID: 16627472 DOI: 10.1074/jbc.m602452200] [Citation(s) in RCA: 136] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
TRPV4 is a cation channel that responds to a variety of stimuli including mechanical forces, temperature, and ligand binding. We set out to identify TRPV4-interacting proteins by performing yeast two-hybrid screens, and we isolated with the avian TRPV4 amino terminus the chicken orthologues of mammalian PACSINs 1 and 3. The PACSINs are a protein family consisting of three members that have been implicated in synaptic vesicular membrane trafficking and regulation of dynamin-mediated endocytotic processes. In biochemical interaction assays we found that all three murine PACSIN isoforms can bind to the amino terminus of rodent TRPV4. No member of the PACSIN protein family was able to biochemically interact with TRPV1 and TRPV2. Co-expression of PACSIN 3, but not PACSINs 1 and 2, shifted the ratio of plasma membrane-associated versus cytosolic TRPV4 toward an apparent increase of plasma membrane-associated TRPV4 protein. A similar shift was also observable when we blocked dynamin-mediated endocytotic processes, suggesting that PACSIN 3 specifically affects the endocytosis of TRPV4, thereby modulating the subcellular localization of the ion channel. Mutational analysis shows that the interaction of the two proteins requires both a TRPV4-specific proline-rich domain upstream of the ankyrin repeats of the channel and the carboxyl-terminal Src homology 3 domain of PACSIN 3. Such a functional interaction could be important in cell types that show distribution of both proteins to the same subcellular regions such as renal tubule cells where the proteins are associated with the luminal plasma membrane.
Collapse
Affiliation(s)
- Math P Cuajungco
- Department of Otolaryngology, Stanford University School of Medicine, Stanford, California 94305, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Frederickson CJ, Cuajungco MP, Frederickson CJ. Is zinc the link between compromises of brain perfusion (excitotoxicity) and Alzheimer's disease? J Alzheimers Dis 2006; 8:155-60; discussion 209-15. [PMID: 16308484 DOI: 10.3233/jad-2005-8208] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Prior brain injury is a major risk factor in the development of Alzheimer's disease. This is true for traumatic brain injury, stroke or ischemic brain injury, and (more speculatively) for brain injury resulting from the hypo-perfusion-reperfusion in cardiac arrest or cardiac bypass surgery and even hypo- or hypertension. Here we propose that the release of excess, toxic, "floods" of free zinc into the brain that occurs during and after all excitotoxic brain injury is a key factor that sets the stage for the later development of Alzheimer's disease. Rapid and aggressive administration of zinc buffering compounds to patients suffering brain injury may therefore not only ameliorate the acute injury but might also reduce the risk of subsequent development of Alzheimer's disease.
Collapse
|
35
|
Abstract
Alzheimer's disease (AD) is associated with the abnormal aggregation of amyloid-beta (Abeta) protein. Abeta and its precursor protein (APP) interact with metal ions such as zinc, copper and iron. Evidence shows that these metals play a role in the precipitation and cytotoxicity of Abeta. Despite recent advances in AD research, there is a lack of therapeutic agents to hinder the apparent aggregation and toxicity of Abeta. Recent studies show that drugs with metal chelating properties could produce a significant reversal of amyloid-beta plaque deposition in vitro and in vivo. Here we discuss the interaction of Abeta with metals, metal dyshomeostasis in the CNS of patients with AD, and the potential therapeutic effects of metal chelators.
Collapse
|
36
|
Slaugenhaupt SA, Mull J, Leyne M, Cuajungco MP, Gill SP, Hims MM, Quintero F, Axelrod FB, Gusella JF. Rescue of a human mRNA splicing defect by the plant cytokinin kinetin. Hum Mol Genet 2003; 13:429-36. [PMID: 14709595 DOI: 10.1093/hmg/ddh046] [Citation(s) in RCA: 123] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
The defective splicing of pre-mRNA is a major cause of human disease. Exon skipping is a common result of splice mutations and has been reported in a wide variety of genetic disorders, yet the underlying mechanism is poorly understood. Often, such mutations are incompletely penetrant, and low levels of normal transcript and protein are maintained. Familial dysautonomia (FD) is caused by mutations in IKBKAP, and all cases described to date involve an intron 20 mutation that results in a unique pattern of tissue-specific exon skipping. Accurate splicing of the mutant IKBKAP allele is particularly inefficient in the nervous system. Here we show that treatment with the plant cytokinin kinetin alters splicing of IKBKAP. Kinetin significantly increases inclusion of exon 20 from the endogenous gene, as well as from an IKBKAP minigene. By contrast the drug does not enhance inclusion of alternatively spliced exon 31 in MYO5A. Benzyladenine, the most closely related cytokinin, showed a similar but less dramatic effect. Our findings reveal a remarkable impact on splicing fidelity by these small molecules, which therefore provide new tools for the dissection of mechanisms controlling tissue-specific pre-mRNA splicing. Further, kinetin should be explored as a treatment for increasing the level of normal IKAP in FD, and for other splicing disorders that may share a similar mechanism.
Collapse
Affiliation(s)
- Susan A Slaugenhaupt
- Molecular Neurogenetics Unit, Center for Human Genetic Research, Massachusetts General Hospital, Charlestown, MA 02129, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Mezey E, Parmalee A, Szalayova I, Gill SP, Cuajungco MP, Leyne M, Slaugenhaupt SA, Brownstein MJ. Of splice and men: what does the distribution of IKAP mRNA in the rat tell us about the pathogenesis of familial dysautonomia? Brain Res 2003; 983:209-14. [PMID: 12914982 DOI: 10.1016/s0006-8993(03)03090-7] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
Familial dysautonomia (FD) is the best-known and most common member of a group of congenital sensory/autonomic neuropathies characterized by widespread sensory and variable autonomic dysfunction. As opposed to the sensory/motor neuropathies, little is known about the causes of neuronal dysfunction and loss in the sensory/autonomic neuropathies. FD involves progressive neuronal degeneration, has a broad impact on the operation of many of the body's systems, and leads to a markedly reduced quality of life and premature death. In 2001, we identified two mutations in the IKBKAP gene that result in FD. IKBKAP encodes IKAP, a member of the putative human holo-Elongator complex, which may facilitate transcription by RNA polymerase II. Whether or not the Elongator plays this role is moot. The FD mutation found on >99.5% of FD chromosomes does not cause complete loss of function. Instead, it results in a tissue-specific decrease in splicing efficiency of the IKBKAP transcript; cells from patients retain some capacity to produce normal mRNA and protein. To better understand the relationship between the genotype of FD patients and their phenotype, we have used in situ hybridization histochemistry to map the IKAP mRNA in sections of whole rat embryos. The mRNA is widely distributed. Highest levels are in the nervous system, but substantial amounts are also present in peripheral organs.
Collapse
Affiliation(s)
- Eva Mezey
- Basic Neuroscience Program, NINDS, NIH, Building 36, Room 3D-06, Bethesda, MD 20892, USA.
| | | | | | | | | | | | | | | |
Collapse
|
38
|
Cuajungco MP, Ando Y, Axelrod FB, Biaggioni I, Goldstein DS, Guttmacher AE, Gwinn-Hardy K, Hahn MK, Hilz MJ, Jacob G, Jens J, Kennedy WR, Liggett SB, O'Connor DT, Peltzer SR, Robertson D, Rubin BY, Scudder Q, Smith LJ, Sonenshein GE, Svejstrup JQ, Xu Y, Slaugenhaupt SA. Hereditary dysautonomias: current knowledge and collaborations for the future. Clin Auton Res 2003; 13:180-95. [PMID: 12822040 DOI: 10.1007/s10286-003-0098-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
The hereditary dysautonomias (H-Dys) are a large group of disorders that affect the autonomic nervous system. Research in the field of H-Dys is very challenging, because the disorders involve interdisciplinary, integrative, and "mind-body" connections. Recently, medical scientists, NIH/NINDS representatives, and several patient support groups gathered for the first time in order to discuss recent findings and future directions in the H-Dys field. The H-Dys workshop was instrumental in promoting interactions between basic science and clinical investigators. It also allowed attendees to have an opportunity to meet each other, understand the similarities between the various forms of dysautonomia, and experience the unique perspective offered by patients and their families. Future advances in H-Dys research will depend on a novel multi-system approach by investigators from different medical disciplines, and it is hoped that towards a common goal, novel "bench-to-bedside" therapeutics will be developed to improve the lives of, or even cure, patients suffering from dysautonomic syndromes.
Collapse
Affiliation(s)
- Math P Cuajungco
- Harvard Institute of Human Genetics, 77 Avenue Louis Pasteur, HIM Building, Room 422, Boston, MA 02115, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Leyne M, Mull J, Gill SP, Cuajungco MP, Oddoux C, Blumenfeld A, Maayan C, Gusella JF, Axelrod FB, Slaugenhaupt SA. Identification of the first non-Jewish mutation in familial Dysautonomia. Am J Med Genet A 2003; 118A:305-8. [PMID: 12687659 DOI: 10.1002/ajmg.a.20052] [Citation(s) in RCA: 56] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
Familial Dysautonomia is an autosomal recessive disease with a remarkably high carrier frequency in the Ashkenazi Jewish population. It has recently been estimated that as many as 1 in 27 Ashkenazi Jews is a carrier of FD. The FD gene has been identified as IKBKAP, and two disease-causing mutations have been identified. The most common mutation, which is present on 99.5% of all FD chromosomes, is an intronic splice site mutation that results in tissue-specific skipping of exon 20. The second mutation, R696P, is a missense mutation that has been identified in 4 unrelated patients heterozygous for the major splice mutation. Interestingly, despite the fact that FD is a recessive disease, normal mRNA and protein are expressed in patient cells. To date, the diagnosis of FD has been limited to individuals of Ashkenazi Jewish descent and identification of the gene has led to widespread diagnostic and carrier testing in this population. In this report, we describe the first non-Jewish IKBKAP mutation, a proline to leucine missense mutation in exon 26, P914L. This mutation is of particular significance because it was identified in a patient who lacks one of the cardinal diagnostic criteria for the disease-pure Ashkenazi Jewish ancestry. In light of this fact, the diagnostic criteria for FD must be expanded. Furthermore, in order to ensure carrier identification in all ethnicities, this mutation must now be considered when screening for FD.
Collapse
Affiliation(s)
- Maire Leyne
- Molecular Neurogenetics Unit, Massachusetts General Hospital, Charlestown, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Cuajungco MP, Leyne M, Mull J, Gill SP, Lu W, Zagzag D, Axelrod FB, Maayan C, Gusella JF, Slaugenhaupt SA. Tissue-specific reduction in splicing efficiency of IKBKAP due to the major mutation associated with familial dysautonomia. Am J Hum Genet 2003; 72:749-58. [PMID: 12577200 PMCID: PMC1180251 DOI: 10.1086/368263] [Citation(s) in RCA: 105] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2002] [Accepted: 12/13/2002] [Indexed: 11/03/2022] Open
Abstract
We recently identified a mutation in the I-kappa B kinase associated protein (IKBKAP) gene as the major cause of familial dysautonomia (FD), a recessive sensory and autonomic neuropathy. This alteration, located at base pair 6 of the intron 20 donor splice site, is present on >99.5% of FD chromosomes and results in tissue-specific skipping of exon 20. A second FD mutation, a missense change in exon 19 (R696P), was seen in only four patients heterozygous for the major mutation. Here, we have further characterized the consequences of the major mutation by examining the ratio of wild-type to mutant (WT:MU) IKBKAP transcript in EBV-transformed lymphoblast lines, primary fibroblasts, freshly collected blood samples, and postmortem tissues from patients with FD. We consistently found that WT IKBKAP transcripts were present, albeit to varying extents, in all cell lines, blood, and postmortem FD tissues. Further, a corresponding decrease in the level of WT protein is seen in FD cell lines and tissues. The WT:MU ratio in cultured lymphoblasts varied with growth phase but not with serum concentration or inclusion of antibiotics. Using both densitometry and real-time quantitative polymerase chain reaction, we found that relative WT:MU IKBKAP RNA levels were highest in cultured patient lymphoblasts and lowest in postmortem central and peripheral nervous tissues. These observations suggest that the relative inefficiency of WT IKBKAP mRNA production from the mutant alleles in the nervous system underlies the selective degeneration of sensory and autonomic neurons in FD.Therefore, exploration of methods to increase the WT:MU IKBKAP transcript ratio in the nervous system offers a promising approach for developing an effective therapy for patients with FD.
Collapse
Affiliation(s)
- Math P. Cuajungco
- Harvard Institute of Human Genetics, Harvard Medical School, and Collis Genome Laboratory, Brigham and Women’s Hospital, Boston; Departments of Pathology and Pediatrics, New York University Medical Center, New York; Department of Pediatrics, Hadassah University Hospital, Jerusalem; and Molecular Neurogenetics Unit, Massachusetts General Hospital, Charlestown, MA
| | - Maire Leyne
- Harvard Institute of Human Genetics, Harvard Medical School, and Collis Genome Laboratory, Brigham and Women’s Hospital, Boston; Departments of Pathology and Pediatrics, New York University Medical Center, New York; Department of Pediatrics, Hadassah University Hospital, Jerusalem; and Molecular Neurogenetics Unit, Massachusetts General Hospital, Charlestown, MA
| | - James Mull
- Harvard Institute of Human Genetics, Harvard Medical School, and Collis Genome Laboratory, Brigham and Women’s Hospital, Boston; Departments of Pathology and Pediatrics, New York University Medical Center, New York; Department of Pediatrics, Hadassah University Hospital, Jerusalem; and Molecular Neurogenetics Unit, Massachusetts General Hospital, Charlestown, MA
| | - Sandra P. Gill
- Harvard Institute of Human Genetics, Harvard Medical School, and Collis Genome Laboratory, Brigham and Women’s Hospital, Boston; Departments of Pathology and Pediatrics, New York University Medical Center, New York; Department of Pediatrics, Hadassah University Hospital, Jerusalem; and Molecular Neurogenetics Unit, Massachusetts General Hospital, Charlestown, MA
| | - Weining Lu
- Harvard Institute of Human Genetics, Harvard Medical School, and Collis Genome Laboratory, Brigham and Women’s Hospital, Boston; Departments of Pathology and Pediatrics, New York University Medical Center, New York; Department of Pediatrics, Hadassah University Hospital, Jerusalem; and Molecular Neurogenetics Unit, Massachusetts General Hospital, Charlestown, MA
| | - David Zagzag
- Harvard Institute of Human Genetics, Harvard Medical School, and Collis Genome Laboratory, Brigham and Women’s Hospital, Boston; Departments of Pathology and Pediatrics, New York University Medical Center, New York; Department of Pediatrics, Hadassah University Hospital, Jerusalem; and Molecular Neurogenetics Unit, Massachusetts General Hospital, Charlestown, MA
| | - Felicia B. Axelrod
- Harvard Institute of Human Genetics, Harvard Medical School, and Collis Genome Laboratory, Brigham and Women’s Hospital, Boston; Departments of Pathology and Pediatrics, New York University Medical Center, New York; Department of Pediatrics, Hadassah University Hospital, Jerusalem; and Molecular Neurogenetics Unit, Massachusetts General Hospital, Charlestown, MA
| | - Channa Maayan
- Harvard Institute of Human Genetics, Harvard Medical School, and Collis Genome Laboratory, Brigham and Women’s Hospital, Boston; Departments of Pathology and Pediatrics, New York University Medical Center, New York; Department of Pediatrics, Hadassah University Hospital, Jerusalem; and Molecular Neurogenetics Unit, Massachusetts General Hospital, Charlestown, MA
| | - James F. Gusella
- Harvard Institute of Human Genetics, Harvard Medical School, and Collis Genome Laboratory, Brigham and Women’s Hospital, Boston; Departments of Pathology and Pediatrics, New York University Medical Center, New York; Department of Pediatrics, Hadassah University Hospital, Jerusalem; and Molecular Neurogenetics Unit, Massachusetts General Hospital, Charlestown, MA
| | - Susan A. Slaugenhaupt
- Harvard Institute of Human Genetics, Harvard Medical School, and Collis Genome Laboratory, Brigham and Women’s Hospital, Boston; Departments of Pathology and Pediatrics, New York University Medical Center, New York; Department of Pediatrics, Hadassah University Hospital, Jerusalem; and Molecular Neurogenetics Unit, Massachusetts General Hospital, Charlestown, MA
| |
Collapse
|
41
|
Abstract
One of us showed previously [Cuajungco and Lees (1998) Brain Res. 799, 188-129] that nitric oxide injected into the cerebrum in vivo causes zinc staining to appear in the somata of neurons and suggested that this staining of somata might be accompanied by a depletion (release) of zinc from axon terminals. In the present study, we confirm earlier results and report that there is a dramatic loss (apparent release) of histologically reactive zinc from the boutons of zinc-containing axons induced by infusion of nitric oxide into the brain in vivo. Rats were anesthetized with halothane and a cannula was inserted into the hippocampus. Either nitric oxide donor (spermineNONOate, 100 mM/2 microl) or control (spermine, 100 mM/2 l) was infused into the hippocampus or the cerebellar cortex. Two hours after infusion, N-(6-methoxy-8-quinolyl)-para-toluenesulfonamide (TSQ) staining for zinc in the brains revealed that sperminenitric oxide, but not control (spermine only) produced up to 95% depletion of zinc staining from the zinc-containing boutons. TSQ-positive neurons were also conspicuous throughout injection sites, in both the cerebral cortex and in the cerebellar cortex, where the Purkinje neurons were especially vivid, despite the scarcity of zinc-containing axonal boutons. It is suggested that the TSQ-stainable zinc in somata might represent intracellular stores mobilized from within or permeating extracellular stores.
Collapse
Affiliation(s)
- C J Frederickson
- Center for Biomedical Engineering, and Department of Anatomy and Neuroscience, University of Texas Medical Branch, 625 Jennie Sealy Hospital, Galveston 77555, USA.
| | | | | | | |
Collapse
|
42
|
Abstract
There is compelling evidence that the etiology of Alzheimer's disease (AD) involves characteristic amyloid-beta (Abeta) deposition, oxidative stress, and anomalous metal-Abeta protein interaction. New studies have implicated redox active metals such as copper, iron, and zinc as key mediating factors in the pathophysiology of Alzheimer's disease. There is also evidence that drugs with metal chelating properties could produce a significant reversal of amyloid-beta plaque deposition in vitro and in vivo. This paper reviews current observations on the etiologic role of zinc in AD. We also discuss the interactions of zinc and copper with Abeta, a factor that purportedly facilitates disease processes. Finally, we review the protective role of zinc against Abeta cytotoxicity and hypothesize how the apparent effect of zinc on AD pathology may be paradoxical, The Zinc Paradox. Indeed, complex pathologic stressors inherent to the Alzheimer's diseased brain dictate whether or not zinc will be neuroprotective or neurodegenerative. Further research on the zinc paradox in AD is needed in order to elucidate the exact role zinc plays in AD pathogenesis.
Collapse
Affiliation(s)
- Math P Cuajungco
- Department of Neurology, Molecular Neurogenetics Unit, Massachusetts General Hospital, Charlestown, MA 02129, USA.
| | | |
Collapse
|
43
|
Frederickson CJ, Suh SW, Koh JY, Cha YK, Thompson RB, LaBuda CJ, Balaji RV, Cuajungco MP. Depletion of intracellular zinc from neurons by use of an extracellular chelator in vivo and in vitro. J Histochem Cytochem 2002; 50:1659-62. [PMID: 12486088 DOI: 10.1177/002215540205001210] [Citation(s) in RCA: 67] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
The membrane-impermeable chelator CaEDTA was introduced extracellularly among neurons in vivo and in vitro for the purpose of chelating extracellular Zn(2+). Unexpectedly, this treatment caused histochemically reactive Zn(2+) in intracellular compartments to drop rapidly. The same general result was seen with intravesicular Zn(2+), which fell after CaEDTA infusion into the lateral ventricle of the brain, with perikaryal Zn(2+) in Purkinje neurons (in vivo) and with cortical neurons (in vitro). These findings suggest either that the volume of zinc ion efflux and reuptake is higher than previously suspected or that EDTA can enter cells and vesicles. Caution is therefore warranted in attempting to manipulate extracellular or intracellular Zn(2+) selectively.
Collapse
|
44
|
Abstract
Our laboratory recently reported that mutations in the human I-kappaB kinase-associated protein (IKBKAP) gene are responsible for familial dysautonomia (FD). Interestingly, amino acid substitutions in the IKAP correlate with increased risk for childhood bronchial asthma. Here, we report the cloning and genomic characterization of the mouse Ikbkap gene, the homolog of human IKBKAP. Like its human counterpart, Ikbkap encodes a protein of 1332 amino acids with a molecular weight of approximately 150 kDa. The Ikbkap gene product, Ikap, contains 37 exons that span approximately 51 kb. The protein shows 80% amino acid identity with human IKAP. It shows very high conservation across species and is homologous to the yeast Elp1/Iki3p protein, which is a member of the Elongator complex. The Ikbkap gene maps to chromosome 4 in a region that is syntenic to human chromosome 9q31.3. Because no animal model of FD currently exists, cloning of the mouse Ikbkap gene is an important first step toward creating a mouse model for FD. In addition, cloning of Ikbkap is crucial to the characterization of the putative mammalian Elongator complex.
Collapse
Affiliation(s)
- M P Cuajungco
- Harvard Institute of Human Genetics and Massachusetts General Hospital, Boston, Massachusetts, USA
| | | | | | | | | | | |
Collapse
|
45
|
Abstract
Alzheimer's disease is a rapidly worsening public health problem. The current lack of effective treatments for Alzheimer's disease makes it imperative to find new pharmacotherapies. At present, the treatment of symptoms includes use of acetylcholinesterase inhibitors, which enhance acetylcholine levels and improve cognitive functioning. Current reports provide evidence that the pathogenesis of Alzheimer's disease is linked to the characteristic neocortical amyloid-beta deposition, which may be mediated by abnormal metal interaction with A beta as well as metal-mediated oxidative stress. In light of these observations, we have considered the development of drugs that target abnormal metal accumulation and its adverse consequences, as well as prevention or reversal of amyloid-beta plaque formation. This paper reviews recent observations on the possible etiologic role of A beta deposition, its redox activity, and its interaction with transition metals that are enriched in the neocortex. We discuss the effects of metal chelators on these processes, list existing drugs with chelating properties, and explore the promise of this approach as a basis for medicinal chemistry in the development of novel Alzheimer's disease therapeutics.
Collapse
Affiliation(s)
- M P Cuajungco
- Laboratory for Oxidation Biology, Massachusetts General Hospital, and Department of Psychiatry, Harvard Medical School, Boston, Massachusetts 02115, USA
| | | | | | | | | |
Collapse
|
46
|
Slaugenhaupt SA, Blumenfeld A, Gill SP, Leyne M, Mull J, Cuajungco MP, Liebert CB, Chadwick B, Idelson M, Reznik L, Robbins CM, Makalowska I, Brownstein MJ, Krappmann D, Scheidereit C, Maayan C, Axelrod FB, Gusella JF. Tissue-specific expression of a splicing mutation in the IKBKAP gene causes familial dysautonomia. Am J Hum Genet 2001; 68:598-605. [PMID: 11179008 PMCID: PMC1274473 DOI: 10.1086/318810] [Citation(s) in RCA: 423] [Impact Index Per Article: 18.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/29/2000] [Accepted: 01/10/2001] [Indexed: 11/04/2022] Open
Abstract
Familial dysautonomia (FD; also known as "Riley-Day syndrome"), an Ashkenazi Jewish disorder, is the best known and most frequent of a group of congenital sensory neuropathies and is characterized by widespread sensory and variable autonomic dysfunction. Previously, we had mapped the FD gene, DYS, to a 0.5-cM region on chromosome 9q31 and had shown that the ethnic bias is due to a founder effect, with >99.5% of disease alleles sharing a common ancestral haplotype. To investigate the molecular basis of FD, we sequenced the minimal candidate region and cloned and characterized its five genes. One of these, IKBKAP, harbors two mutations that can cause FD. The major haplotype mutation is located in the donor splice site of intron 20. This mutation can result in skipping of exon 20 in the mRNA of patients with FD, although they continue to express varying levels of wild-type message in a tissue-specific manner. RNA isolated from lymphoblasts of patients is primarily wild-type, whereas only the deleted message is seen in RNA isolated from brain. The mutation associated with the minor haplotype in four patients is a missense (R696P) mutation in exon 19, which is predicted to disrupt a potential phosphorylation site. Our findings indicate that almost all cases of FD are caused by an unusual splice defect that displays tissue-specific expression; and they also provide the basis for rapid carrier screening in the Ashkenazi Jewish population.
Collapse
Affiliation(s)
- Susan A. Slaugenhaupt
- Molecular Neurogenetics Unit, Massachusetts General Hospital, Charlestown; Harvard Institute of Human Genetics, Harvard Medical School, Boston; Departments of Clinical Biochemistry and Pediatrics, Hadassah University Hospital, Jerusalem; Laboratory of Genetics, National Institute of Mental Health and National Human Genome Research Institute, and Genome Technology Branch, National Human Genome Research Institute, and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda; Max-Delbrück-Centrum for Molecular Medicine, Berlin; and Department of Pediatrics, New York University Medical Center, New York
| | - Anat Blumenfeld
- Molecular Neurogenetics Unit, Massachusetts General Hospital, Charlestown; Harvard Institute of Human Genetics, Harvard Medical School, Boston; Departments of Clinical Biochemistry and Pediatrics, Hadassah University Hospital, Jerusalem; Laboratory of Genetics, National Institute of Mental Health and National Human Genome Research Institute, and Genome Technology Branch, National Human Genome Research Institute, and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda; Max-Delbrück-Centrum for Molecular Medicine, Berlin; and Department of Pediatrics, New York University Medical Center, New York
| | - Sandra P. Gill
- Molecular Neurogenetics Unit, Massachusetts General Hospital, Charlestown; Harvard Institute of Human Genetics, Harvard Medical School, Boston; Departments of Clinical Biochemistry and Pediatrics, Hadassah University Hospital, Jerusalem; Laboratory of Genetics, National Institute of Mental Health and National Human Genome Research Institute, and Genome Technology Branch, National Human Genome Research Institute, and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda; Max-Delbrück-Centrum for Molecular Medicine, Berlin; and Department of Pediatrics, New York University Medical Center, New York
| | - Maire Leyne
- Molecular Neurogenetics Unit, Massachusetts General Hospital, Charlestown; Harvard Institute of Human Genetics, Harvard Medical School, Boston; Departments of Clinical Biochemistry and Pediatrics, Hadassah University Hospital, Jerusalem; Laboratory of Genetics, National Institute of Mental Health and National Human Genome Research Institute, and Genome Technology Branch, National Human Genome Research Institute, and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda; Max-Delbrück-Centrum for Molecular Medicine, Berlin; and Department of Pediatrics, New York University Medical Center, New York
| | - James Mull
- Molecular Neurogenetics Unit, Massachusetts General Hospital, Charlestown; Harvard Institute of Human Genetics, Harvard Medical School, Boston; Departments of Clinical Biochemistry and Pediatrics, Hadassah University Hospital, Jerusalem; Laboratory of Genetics, National Institute of Mental Health and National Human Genome Research Institute, and Genome Technology Branch, National Human Genome Research Institute, and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda; Max-Delbrück-Centrum for Molecular Medicine, Berlin; and Department of Pediatrics, New York University Medical Center, New York
| | - Math P. Cuajungco
- Molecular Neurogenetics Unit, Massachusetts General Hospital, Charlestown; Harvard Institute of Human Genetics, Harvard Medical School, Boston; Departments of Clinical Biochemistry and Pediatrics, Hadassah University Hospital, Jerusalem; Laboratory of Genetics, National Institute of Mental Health and National Human Genome Research Institute, and Genome Technology Branch, National Human Genome Research Institute, and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda; Max-Delbrück-Centrum for Molecular Medicine, Berlin; and Department of Pediatrics, New York University Medical Center, New York
| | - Christopher B. Liebert
- Molecular Neurogenetics Unit, Massachusetts General Hospital, Charlestown; Harvard Institute of Human Genetics, Harvard Medical School, Boston; Departments of Clinical Biochemistry and Pediatrics, Hadassah University Hospital, Jerusalem; Laboratory of Genetics, National Institute of Mental Health and National Human Genome Research Institute, and Genome Technology Branch, National Human Genome Research Institute, and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda; Max-Delbrück-Centrum for Molecular Medicine, Berlin; and Department of Pediatrics, New York University Medical Center, New York
| | - Brian Chadwick
- Molecular Neurogenetics Unit, Massachusetts General Hospital, Charlestown; Harvard Institute of Human Genetics, Harvard Medical School, Boston; Departments of Clinical Biochemistry and Pediatrics, Hadassah University Hospital, Jerusalem; Laboratory of Genetics, National Institute of Mental Health and National Human Genome Research Institute, and Genome Technology Branch, National Human Genome Research Institute, and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda; Max-Delbrück-Centrum for Molecular Medicine, Berlin; and Department of Pediatrics, New York University Medical Center, New York
| | - Maria Idelson
- Molecular Neurogenetics Unit, Massachusetts General Hospital, Charlestown; Harvard Institute of Human Genetics, Harvard Medical School, Boston; Departments of Clinical Biochemistry and Pediatrics, Hadassah University Hospital, Jerusalem; Laboratory of Genetics, National Institute of Mental Health and National Human Genome Research Institute, and Genome Technology Branch, National Human Genome Research Institute, and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda; Max-Delbrück-Centrum for Molecular Medicine, Berlin; and Department of Pediatrics, New York University Medical Center, New York
| | - Luba Reznik
- Molecular Neurogenetics Unit, Massachusetts General Hospital, Charlestown; Harvard Institute of Human Genetics, Harvard Medical School, Boston; Departments of Clinical Biochemistry and Pediatrics, Hadassah University Hospital, Jerusalem; Laboratory of Genetics, National Institute of Mental Health and National Human Genome Research Institute, and Genome Technology Branch, National Human Genome Research Institute, and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda; Max-Delbrück-Centrum for Molecular Medicine, Berlin; and Department of Pediatrics, New York University Medical Center, New York
| | - Christiane M. Robbins
- Molecular Neurogenetics Unit, Massachusetts General Hospital, Charlestown; Harvard Institute of Human Genetics, Harvard Medical School, Boston; Departments of Clinical Biochemistry and Pediatrics, Hadassah University Hospital, Jerusalem; Laboratory of Genetics, National Institute of Mental Health and National Human Genome Research Institute, and Genome Technology Branch, National Human Genome Research Institute, and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda; Max-Delbrück-Centrum for Molecular Medicine, Berlin; and Department of Pediatrics, New York University Medical Center, New York
| | - Izabela Makalowska
- Molecular Neurogenetics Unit, Massachusetts General Hospital, Charlestown; Harvard Institute of Human Genetics, Harvard Medical School, Boston; Departments of Clinical Biochemistry and Pediatrics, Hadassah University Hospital, Jerusalem; Laboratory of Genetics, National Institute of Mental Health and National Human Genome Research Institute, and Genome Technology Branch, National Human Genome Research Institute, and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda; Max-Delbrück-Centrum for Molecular Medicine, Berlin; and Department of Pediatrics, New York University Medical Center, New York
| | - Michael J. Brownstein
- Molecular Neurogenetics Unit, Massachusetts General Hospital, Charlestown; Harvard Institute of Human Genetics, Harvard Medical School, Boston; Departments of Clinical Biochemistry and Pediatrics, Hadassah University Hospital, Jerusalem; Laboratory of Genetics, National Institute of Mental Health and National Human Genome Research Institute, and Genome Technology Branch, National Human Genome Research Institute, and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda; Max-Delbrück-Centrum for Molecular Medicine, Berlin; and Department of Pediatrics, New York University Medical Center, New York
| | - Daniel Krappmann
- Molecular Neurogenetics Unit, Massachusetts General Hospital, Charlestown; Harvard Institute of Human Genetics, Harvard Medical School, Boston; Departments of Clinical Biochemistry and Pediatrics, Hadassah University Hospital, Jerusalem; Laboratory of Genetics, National Institute of Mental Health and National Human Genome Research Institute, and Genome Technology Branch, National Human Genome Research Institute, and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda; Max-Delbrück-Centrum for Molecular Medicine, Berlin; and Department of Pediatrics, New York University Medical Center, New York
| | - Claus Scheidereit
- Molecular Neurogenetics Unit, Massachusetts General Hospital, Charlestown; Harvard Institute of Human Genetics, Harvard Medical School, Boston; Departments of Clinical Biochemistry and Pediatrics, Hadassah University Hospital, Jerusalem; Laboratory of Genetics, National Institute of Mental Health and National Human Genome Research Institute, and Genome Technology Branch, National Human Genome Research Institute, and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda; Max-Delbrück-Centrum for Molecular Medicine, Berlin; and Department of Pediatrics, New York University Medical Center, New York
| | - Channa Maayan
- Molecular Neurogenetics Unit, Massachusetts General Hospital, Charlestown; Harvard Institute of Human Genetics, Harvard Medical School, Boston; Departments of Clinical Biochemistry and Pediatrics, Hadassah University Hospital, Jerusalem; Laboratory of Genetics, National Institute of Mental Health and National Human Genome Research Institute, and Genome Technology Branch, National Human Genome Research Institute, and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda; Max-Delbrück-Centrum for Molecular Medicine, Berlin; and Department of Pediatrics, New York University Medical Center, New York
| | - Felicia B. Axelrod
- Molecular Neurogenetics Unit, Massachusetts General Hospital, Charlestown; Harvard Institute of Human Genetics, Harvard Medical School, Boston; Departments of Clinical Biochemistry and Pediatrics, Hadassah University Hospital, Jerusalem; Laboratory of Genetics, National Institute of Mental Health and National Human Genome Research Institute, and Genome Technology Branch, National Human Genome Research Institute, and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda; Max-Delbrück-Centrum for Molecular Medicine, Berlin; and Department of Pediatrics, New York University Medical Center, New York
| | - James F. Gusella
- Molecular Neurogenetics Unit, Massachusetts General Hospital, Charlestown; Harvard Institute of Human Genetics, Harvard Medical School, Boston; Departments of Clinical Biochemistry and Pediatrics, Hadassah University Hospital, Jerusalem; Laboratory of Genetics, National Institute of Mental Health and National Human Genome Research Institute, and Genome Technology Branch, National Human Genome Research Institute, and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda; Max-Delbrück-Centrum for Molecular Medicine, Berlin; and Department of Pediatrics, New York University Medical Center, New York
| |
Collapse
|
47
|
Cuajungco MP, Goldstein LE, Nunomura A, Smith MA, Lim JT, Atwood CS, Huang X, Farrag YW, Perry G, Bush AI. Evidence that the beta-amyloid plaques of Alzheimer's disease represent the redox-silencing and entombment of abeta by zinc. J Biol Chem 2000; 275:19439-42. [PMID: 10801774 DOI: 10.1074/jbc.c000165200] [Citation(s) in RCA: 307] [Impact Index Per Article: 12.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Abeta binds Zn(2+), Cu(2+), and Fe(3+) in vitro, and these metals are markedly elevated in the neocortex and especially enriched in amyloid plaque deposits of individuals with Alzheimer's disease (AD). Zn(2+) precipitates Abeta in vitro, and Cu(2+) interaction with Abeta promotes its neurotoxicity, correlating with metal reduction and the cell-free generation of H(2)O(2) (Abeta1-42 > Abeta1-40 > ratAbeta1-40). Because Zn(2+) is redox-inert, we studied the possibility that it may play an inhibitory role in H(2)O(2)-mediated Abeta toxicity. In competition to the cytotoxic potentiation caused by coincubation with Cu(2+), Zn(2+) rescued primary cortical and human embryonic kidney 293 cells that were exposed to Abeta1-42, correlating with the effect of Zn(2+) in suppressing Cu(2+)-dependent H(2)O(2) formation from Abeta1-42. Since plaques contain exceptionally high concentrations of Zn(2+), we examined the relationship between oxidation (8-OH guanosine) levels in AD-affected tissue and histological amyloid burden and found a significant negative correlation. These data suggest a protective role for Zn(2+) in AD, where plaques form as the result of a more robust Zn(2+) antioxidant response to the underlying oxidative attack.
Collapse
Affiliation(s)
- M P Cuajungco
- Laboratory for Oxidation Biology, Genetics and Aging Unit, Massachusetts General Hospital, Charlestown, Massachusetts 02129, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Abstract
Alzheimer's disease (AD) is characterized by amyloid deposits within the neocortical parenchyma and the cerebrovasculature. The main component of these predominantly extracellular collections, Abeta, which is normally a soluble component of all biological fluids, is cleaved out of a ubiquitously expressed parent protein, the amyloid protein precursor (APP), one of the type 1 integral membrane glycoproteins. Considerable evidence has indicated that there is zinc dyshomeostasis and abnormal cellular zinc mobilization in AD. We have characterized both APP and Abeta as copper/zinc metalloproteins. Zinc, copper and iron have recently been reported to be concentrated to 0.5 to 1 mmol/L in amyloid plaque. In vitro, rapid Abeta aggregation is mediated by Zn(II), promoted by the alpha-helical structure of Abeta, and is reversible with chelation. In addition, Abeta produces hydrogen peroxide in a Cu(II)/Fe(III)-dependent manner, and the hydrogen peroxide formation is quenched by Zn(II). Moreover, zinc preserves the nontoxic properties of Abeta. Although the zinc-binding proteins apolipoprotein E epsilon4 allele and alpha(2)-macroglobulin have been characterized as two genetic risk factors for AD, zinc exposure as a risk factor for AD has not been rigorously studied. Based on our findings, we envisage that zinc may serve twin roles by both initiating amyloid deposition and then being involved in mechanisms attempting to quench oxidative stress and neurotoxicity derived from the amyloid mass. Hence, it remains debatable whether zinc supplementation is beneficial or deleterious for AD until additional studies clarify the issue.
Collapse
Affiliation(s)
- X Huang
- Laboratory for Oxidation Biology, Genetics and Aging Unit, Department of Psychiatry, Harvard Medical School, Massachusetts General Hospital, Charleston, MA 02129, USA
| | | | | | | | | | | |
Collapse
|
49
|
Huang X, Cuajungco MP, Atwood CS, Hartshorn MA, Tyndall JD, Hanson GR, Stokes KC, Leopold M, Multhaup G, Goldstein LE, Scarpa RC, Saunders AJ, Lim J, Moir RD, Glabe C, Bowden EF, Masters CL, Fairlie DP, Tanzi RE, Bush AI. Cu(II) potentiation of alzheimer abeta neurotoxicity. Correlation with cell-free hydrogen peroxide production and metal reduction. J Biol Chem 1999; 274:37111-6. [PMID: 10601271 DOI: 10.1074/jbc.274.52.37111] [Citation(s) in RCA: 568] [Impact Index Per Article: 22.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023] Open
Abstract
Oxidative stress markers as well as high concentrations of copper are found in the vicinity of Abeta amyloid deposits in Alzheimer's disease. The neurotoxicity of Abeta in cell culture has been linked to H(2)O(2) generation by an unknown mechanism. We now report that Cu(II) markedly potentiates the neurotoxicity exhibited by Abeta in cell culture. The potentiation of toxicity is greatest for Abeta1-42 > Abeta1-40 >> mouse/rat Abeta1-40, corresponding to their relative capacities to reduce Cu(II) to Cu(I), form H(2)O(2) in cell-free assays and to exhibit amyloid pathology. The copper complex of Abeta1-42 has a highly positive formal reduction potential ( approximately +500-550 mV versus Ag/AgCl) characteristic of strongly reducing cuproproteins. These findings suggest that certain redox active metal ions may be important in exacerbating and perhaps facilitating Abeta-mediated oxidative damage in Alzheimer's disease.
Collapse
Affiliation(s)
- X Huang
- Laboratory for Oxidation Biology, Genetics and Aging Unit, and Department of Psychiatry, Harvard Medical School, Massachusetts General Hospital, Charlestown, Massachusetts 02129, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Huang X, Atwood CS, Hartshorn MA, Multhaup G, Goldstein LE, Scarpa RC, Cuajungco MP, Gray DN, Lim J, Moir RD, Tanzi RE, Bush AI. The A beta peptide of Alzheimer's disease directly produces hydrogen peroxide through metal ion reduction. Biochemistry 1999; 38:7609-16. [PMID: 10386999 DOI: 10.1021/bi990438f] [Citation(s) in RCA: 803] [Impact Index Per Article: 32.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
Oxidative stress markers characterize the neuropathology both of Alzheimer's disease and of amyloid-bearing transgenic mice. The neurotoxicity of amyloid A beta peptides has been linked to peroxide generation in cell cultures by an unknown mechanism. We now show that human A beta directly produces hydrogen peroxide (H2O2) by a mechanism that involves the reduction of metal ions, Fe(III) or Cu(II), setting up conditions for Fenton-type chemistry. Spectrophotometric experiments establish that the A beta peptide reduces Fe(III) and Cu(II) to Fe(II) and Cu(I), respectively. Spectrochemical techniques are used to show that molecular oxygen is then trapped by A beta and reduced to H2O2 in a reaction that is driven by substoichiometric amounts of Fe(II) or Cu(I). In the presence of Cu(II) or Fe(III), A beta produces a positive thiobarbituric-reactive substance (TBARS) assay, compatible with the generation of the hydroxyl radical (OH.). The amounts of both reduced metal and TBARS reactivity are greatest when generated by A beta 1-42 >> A beta 1-40 > rat A beta 1-40, a chemical relationship that correlates with the participation of the native peptides in amyloid pathology. These findings indicate that the accumulation of A beta could be a direct source of oxidative stress in Alzheimer's disease.
Collapse
Affiliation(s)
- X Huang
- Laboratory for Oxidation Biology, Genetics and Aging Unit, Massachusetts General Hospital, Charlestown 02129, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|